American Century Companies Inc. Boosts Holdings in Biohaven Ltd. $BHVN

American Century Companies Inc. raised its holdings in Biohaven Ltd. (NYSE:BHVN) by 1.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 566,501 shares of the company’s stock after buying an additional 7,740 shares during the quarter. American Century Companies Inc. owned approximately 0.56% of Biohaven worth $13,619,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BHVN. Parallel Advisors LLC grew its holdings in Biohaven by 319.8% in the 1st quarter. Parallel Advisors LLC now owns 1,360 shares of the company’s stock valued at $33,000 after buying an additional 1,036 shares during the period. PNC Financial Services Group Inc. grew its holdings in Biohaven by 53.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,783 shares of the company’s stock valued at $43,000 after buying an additional 623 shares during the period. IFP Advisors Inc grew its holdings in Biohaven by 84,800.0% in the 1st quarter. IFP Advisors Inc now owns 2,547 shares of the company’s stock valued at $61,000 after buying an additional 2,544 shares during the period. KBC Group NV grew its holdings in Biohaven by 35.0% in the 1st quarter. KBC Group NV now owns 4,560 shares of the company’s stock valued at $110,000 after buying an additional 1,183 shares during the period. Finally, Quarry LP purchased a new stake in Biohaven in the 4th quarter valued at about $112,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Wall Street Analysts Forecast Growth

BHVN has been the subject of several recent analyst reports. BTIG Research lifted their price target on Biohaven from $59.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 19th. Royal Bank Of Canada lowered Biohaven from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $54.00 to $21.00 in a research note on Monday, May 19th. Leerink Partners reduced their price objective on Biohaven from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th. Cantor Fitzgerald raised Biohaven to a “strong-buy” rating in a research note on Tuesday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective (down from $54.00) on shares of Biohaven in a research note on Tuesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $54.23.

Biohaven Stock Performance

NYSE BHVN opened at $14.96 on Tuesday. The firm has a market capitalization of $1.58 billion, a P/E ratio of -1.95 and a beta of 0.98. Biohaven Ltd. has a 1-year low of $12.79 and a 1-year high of $55.70. The company has a debt-to-equity ratio of 1.91, a current ratio of 3.82 and a quick ratio of 3.82. The business’s 50-day simple moving average is $14.41 and its 200-day simple moving average is $20.72.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Monday, August 11th. The company reported ($1.94) EPS for the quarter, hitting the consensus estimate of ($1.94). Equities analysts predict that Biohaven Ltd. will post -8.9 EPS for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.